Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023.
Journal
Intestinal research
Journal Volume
22
Journal Issue
3
Pages
213 - 249
ISSN
1598-9100
Date Issued
2024-07
Author(s)
Yen, Hsu-Heng
Wu, Jia-Feng
Wang, Horng-Yuan
Chang, Ting-An
Chang, Chung-Hsin
Chang, Chen-Wang
Chao, Te-Hsin
Chou, Jen-Wei
Chou, Yenn-Hwei
Chuang, Chiao-Hsiung
Hsu, Wen-Hung
Hsu, Tzu-Chi
Huang, Tien-Yu
Hung, Tsung-I
Le, Puo-Hsien
Lin, Chun-Che
Lin, Chun-Chi
Lin, Ching-Pin
Lin, Jen-Kou
Lin, Wei-Chen
Ni, Yen-Hsuan
Shih, I-Lun
Tsai, Tzung-Jiun
Wang, Cheng-Yi
Wu, Deng-Chyang
Abstract
Ulcerative colitis (UC) is a chronic inflammation of the gastrointestinal tract and is characterized by alternating periods of inflammation and remission. Although UC incidence is lower in Taiwan than in Western countries, its impact remains considerable, demanding updated guidelines for addressing local healthcare challenges and patient needs. The revised guidelines employ international standards and recent research, emphasizing practical implementation within the Taiwanese healthcare system. Since the inception of the guidelines in 2017, the Taiwan Society of Inflammatory Bowel Disease has acknowledged the need for ongoing revisions to incorporate emerging therapeutic options and evolving disease management practices. This updated guideline aims to align UC management with local contexts, ensuring comprehensive and context-specific recommendations, thereby raising the standard of care for UC patients in Taiwan. By adapting and optimizing international protocols for local relevance, these efforts seek to enhance health outcomes for patients with UC.
Subjects
Consensus
Guidelines
Management
Taiwan
Ulcerative colitis
Type
journal article